Cervical Cancer: Pembrolizumab Plus Chemoradiotherapy - Phase III Trial
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
KEYNOTE-A18 Phase III Trial Results
- July 19, 2023
On July 19, 2023, Merck announced results from KEYNOTE-A18/ENGOT-cx11/GOG-3047, a Phase III randomized trial evaluating pembrolizumab plus concurrent chemoradiotherapy versus placebo plus chemoradiotherapy in high-risk, locally advanced cervical cancer.
Trial Design
Patient Population: High-risk, locally advanced cervical cancer (newly diagnosed)
Treatment Arms:
- Pembrolizumab plus concurrent chemoradiotherapy
- Versus Placebo plus concurrent chemoradiotherapy
Primary Endpoints: Progression-free survival, overall survival
Secondary Endpoints: Complete response rate, objective response rate, safety
Key Interim Analysis Results
Progression-Free Survival: Pembrolizumab plus chemoradiotherapy demonstrated improved PFS versus placebo-chemoradiotherapy arm
Overall Survival: Interim data immature for final analysis
Safety Profile
Adverse events consistent with established immunotherapy and chemoradiotherapy safety data. No novel or unexpected toxicities identified.
Clinical Significance
According to Merck's Gursel Aktan: Pembrolizumab has established efficacy in recurrent/metastatic cervical cancer. KEYNOTE-A18 demonstrates pembrolizumab benefit extends to newly diagnosed, locally advanced cervical cancer, potentially expanding treatment paradigm to earlier disease stages.
Data Source
https://www.businesswire.com/news/home/20230719399142/en/
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.